[HTML][HTML] Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of …
RK Kelley, B Sangro, W Harris, M Ikeda… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2021•ncbi.nlm.nih.gov
PURPOSE This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte–
associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-
1 monoclonal antibody) as monotherapies and in combination for patients with unresectable
hepatocellular carcinoma (HCC), including a novel regimen featuring a single, priming dose
of tremelimumab (ClinicalTrials. gov identifier:
associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-
1 monoclonal antibody) as monotherapies and in combination for patients with unresectable
hepatocellular carcinoma (HCC), including a novel regimen featuring a single, priming dose
of tremelimumab (ClinicalTrials. gov identifier:
PURPOSE
This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unresectable hepatocellular carcinoma (HCC), including a novel regimen featuring a single, priming dose of tremelimumab (ClinicalTrials. gov identifier:
ncbi.nlm.nih.gov